- change ups
Items Tagged with 'Xeljanz'
Sales of Xeljanz will offset losses due to expiring patents such as Lipitor.
The new rheumatoid arthritis drug from Pfizer — Xeljanz — which has just been approved by the Food and Drug Administration, is predicted to yield sales of more than $2 billion a year in a few years. That good news for Pfizer, however, is offset by the fact Pfizer is facing near-term challenges due to expiring patents, resulting in new competition from generic drugs. Read More